scholarly journals Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib

2013 ◽  
pp. 1197 ◽  
Author(s):  
Marcia Hall ◽  
Heather Shaw
Keyword(s):  
Ovarian Cancer ◽  
Potential Role ◽  
Treatment Options ◽  
Recurrent Ovarian Cancer

scholarly journals Potential role of miR-9 and miR-223 in recurrent ovarian cancer

2008 ◽  
Vol 7 (1) ◽  
pp. 35 ◽  
Author(s):  
Alexandros Laios ◽  
Sharon O'Toole ◽  
Richard Flavin ◽  
Cara Martin ◽  
Lynn Kelly ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Potential Role ◽  
Recurrent Ovarian Cancer

Rational Use of Cytotoxic Chemotherapy for Recurrent Ovarian Cancer

2006 ◽  
Vol 4 (9) ◽  
pp. 947-953 ◽  
Author(s):  
Joyce Liu ◽  
Ursula Matulonis
Keyword(s):  
Ovarian Cancer ◽  
Treatment Options ◽  
Recurrent Ovarian Cancer ◽  
Disease Recurrence ◽  
The United States ◽  
Phase Iii ◽  
Optimal Timing ◽  
Duration Of Treatment ◽  
Phase Iii Trials

Ovarian cancer remains the leading cause of death among women with gynecologic malignancies, and the fifth leading cause of cancer mortality in women in the United States. Although many patients respond to first-line platinum-based therapy, most will experience disease recurrence. The role of further therapy in the setting of recurrent ovarian cancer is palliative, and large randomized phase III trials on treatment options for recurrent ovarian cancer are rare. Controversies exist as to the optimal timing and duration of treatment, and many issues regarding treatment of recurrent disease remain.

ROLE OF ULTRASOUND IN THE DETECTION OF RECURRENT OVARIAN CANCER

2020 ◽  
Vol 6 (1) ◽  
pp. 23-31
Author(s):  
M. Alisherova ◽  
◽  
M. Ismailova
Keyword(s):  
Ovarian Cancer ◽  
Surgical Treatment ◽  
Reproductive System ◽  
Malignant Tumors ◽  
Recurrent Ovarian Cancer ◽  
Primary Diagnosis ◽  
Female Reproductive System

Currently, there are no standard approaches to monitoring patients with ovarian cancer (OC). While the role of ultrasound (US) has been identified in the primary diagnosis of OS, it is still controversial during the subsequent surgical treatment of OC. In world statistics, ovarian cancer is consistently among the four main localizations of malignant tumors of the female reproductive system, along with tumors of the breast, body and cervix.

Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review

2019 ◽  
Vol 152 (2) ◽  
pp. 416-425 ◽  
Author(s):  
Mary M. Mullen ◽  
Lindsay M. Kuroki ◽  
Premal H. Thaker
Keyword(s):  
Ovarian Cancer ◽  
Treatment Options ◽  
Recurrent Ovarian Cancer ◽  
Platinum Sensitive ◽  
Novel Treatment

scholarly journals Correction: Potential Role of Estrogen Receptor Beta as a Tumor Suppressor of Epithelial Ovarian Cancer

PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
Author(s):  
Carine Bossard ◽  
Muriel Busson ◽  
David Vindrieux ◽  
Françoise Gaudin ◽  
Véronique Machelon ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Estrogen Receptor ◽  
Tumor Suppressor ◽  
Epithelial Ovarian Cancer ◽  
Potential Role ◽  
Estrogen Receptor Beta ◽  
Receptor Beta ◽  
Correction Potential

Role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer

2012 ◽  
Vol 125 ◽  
pp. S107
Author(s):  
V. Kolev ◽  
E. Pereira ◽  
S. Roayaie ◽  
D. Labow ◽  
M. Schwartz ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Liver Resection ◽  
Recurrent Ovarian Cancer

Role of external beam radiation therapy (XRT) for palliation in recurrent ovarian cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e19669-e19669
Author(s):  
S. Bush ◽  
N. Jegadeesh ◽  
J. Bandyopadhyay ◽  
M. S. Macfee ◽  
S. A. Ghamande
Keyword(s):  
Ovarian Cancer ◽  
Radiation Therapy ◽  
Recurrent Ovarian Cancer ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation

Clinical Trials in Recurrent Ovarian Cancer

2011 ◽  
Vol 21 (4) ◽  
pp. 771-775 ◽  
Author(s):  
Michael Friedlander ◽  
Edward Trimble ◽  
Anna Tinker ◽  
David Alberts ◽  
Elisabeth Avall-Lundqvist ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Gynecologic Cancer ◽  
Recurrent Ovarian Cancer ◽  
Consensus Conference ◽  
Ca 125 ◽  
Therapeutic Approaches ◽  
Cooperative Research ◽  
International Consensus

The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

Sign in / Sign up

Export Citation Format

Share Document